The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study

Yang, Liu; Lv, Zhenye; Xia, Wenjie; Zhang, W.; Yin, Xiaoyi; Yuan, Hang; Chen, Y.; Hu, Xinye; Lv, Yan; Xu, Qiuran; Weng, Xun; Ni, Chao

doi:10.1007/s12094-017-1806-z

Cited by 26 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, we did not find a significant association between menopause status, tumor site, hormone receptor, HER2 expression status, and CTCs ( P > .05). In addition, compared with our previous data, 75% of MBC patients had CTC numbers greater than 5/7.5 mL of PB . Here, we found that 31.1% (9/29) of patients had CTC numbers greater than 5/7.5 mL of blood.…”

Section: Resultssupporting

confidence: 50%

“…In addition, compared with our previous data, 75% of MBC patients had CTC numbers greater than 5/7.5 mL of PB. 21 Here, we found that 31.1% (9/29) of patients had CTC numbers greater than 5/7.5 mL of blood.…”

Section: Patient Characteristics and Ctc Evaluation At Baselinementioning

confidence: 49%

“…However, it has been reported that CTCs undergoing epithelial to mesenchymal transition could partially or completely lose epithelial markers and would exhibit greater metastatic potential, which could be omitted by the CellSearch technique . Based on our previous study with the CanPatrol system, the nonepithelial‐type CTCs could account for half of the total numbers in MBC patients . Thus, it is necessary to identify both epithelial and nonepithelial (intermediate and mesenchymal type) CTCs.…”

Section: Introductionmentioning

confidence: 99%

“…20 Based on our previous study with the CanPatrol system, the nonepithelial-type CTCs could account for half of the total numbers in MBC patients. 21 Thus, it is necessary to identify both epithelial and nonepithelial (intermediate and mesenchymal type) CTCs.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer

Fang

Zhang

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Although unequivocal evidence has shown the prognostic relevance of circulating tumor cells (CTCs) in patients with metastatic breast cancer (MBC), less evidence is available for its significance in neoadjuvant chemotherapy (NCT) in early breast cancer (BC). Here we conducted an analysis of individual data from 86 patients confirmed as invasive BC by core‐needle biopsy in Zhejiang Provincial People's Hospital between June 2013 and January 2017. The CTCs were assessed at the time after diagnosis and before surgery with the CanPatrol technique. The median follow‐up duration was 46.3 months. CTCs were detected in 37.2% of all patients (29/78) at baseline, and the presence of CTCs was associated with tumor size, tumor stage, and molecular classification. After NCT, the CTC‐positive patients were dropped from 29 to 8, and the EC‐T (epirubicin/cyclophosphamide followed by docetaxel) and TEC (docetaxel/epirubicin/cyclophosphamide) strategies reduce CTC‐positive patients from 16 to 3 and 13 to 5, respectively. The CTC‐negative conversion rates were similar in ER/PR+ HER2+ (5/7, 71.4%), ER/PR− HER2+ (8/11, 72.7%), and TNBC (7/10, 70%) during NCT. In addition, we explored the association between CTC‐negative conversion and objective response rate (partial response and complete response, ORR) and pathological complete response rate (pCR), and our results indicate that ORR was higher in patients with positive CTCs and converted to negative after NCT (ORR, P = .013; pCR, P = .0608). Our study preliminarily highlights the relevance of CTC status and NCT effectiveness in early BC using the CanPatrol system.

show abstract

Section: Resultssupporting

confidence: 50%

Section: Patient Characteristics and Ctc Evaluation At Baselinementioning

confidence: 49%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer

Fang

Zhang

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Though the impact of platelet inhibition on CTC did not correlate with the platelet inhibition, aspirin therapy was favorable in reducing the release of platelet-angiogenic proteins ( 94 , 115 ). Another phase II trial with metastatic cancer patients reported that aspirin treatment significantly reduced CTC numbers in metastatic CRC but did not have significance in metastatic breast cancer ( 116 ).…”

Section: Platelet Metabolism Targeted Non-steroidal Anti-inflammatorymentioning

confidence: 99%

Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy

et al. 2018

View full text Add to dashboard Cite

The role of platelets in cancer progression has been well recognized in the field of cancer biology. Emerging studies are elaborating further the additional roles and added extent that platelets play in promoting tumorigenesis. Platelets release factors that support tumor growth and also form heterotypic aggregates with tumor cells, which can provide an immune-evasive advantage. Their most critical role may be the inhibition of immune cell function that can negatively impact the body’s ability in preventing tumor establishment and growth. This review summarizes the importance of platelets in tumor progression, therapeutic response, survival, and finally the notion of immunotherapy modulation being likely to benefit from the inclusion of platelet inhibitors.

show abstract

Fast Mimicking Diets and Other Innovative Nutritional Interventions to Treat Patients with Breast Cancer

Giugliano,

Boldrini,

Uliano

et al. 2023

Cancer Treatment and Research

View full text Add to dashboard Cite

The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study

Abstract: Aspirin could decrease CTCs numbers and block EMT transition in MCC patients and part of MBC patients.

Cited by 26 publications

References 29 publications

Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer

Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer

Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy

Fast Mimicking Diets and Other Innovative Nutritional Interventions to Treat Patients with Breast Cancer

Contact Info

Product

Resources

About